Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine

Inclusion Criteria:

- Type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to Visit 2
(randomisation)

- Currently treated with IGlar (Insulin Glargine) and up to 3 oral antidiabetic drugs
(OADs) (metformin, DPP-4 inhibitor, sulphonylurea/glinide or alpha-glucosidase
inhibitor). All antidiabetic treatments should have been ongoing for at least 12 weeks
prior to Visit 2 (randomisation) and doses should have been stable in this period of
time

- Glycosylated haemoglobin (HbA1c) 7.0-10.0% (both inclusive) by central laboratory
analysis

- Body mass index (BMI) below or equal to 40 kg/m^2

Exclusion Criteria:

- Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists or thiazolidinediones
(TZDs) both within the last 12 weeks prior to Visit 2 (randomisation)

- Stroke; heart failure New York Heart Association (NYHA) class III or IV; myocardial
infarction; unstable angina pectoris; or coronary arterial bypass graft or
angioplasty; all within the last 24 weeks prior to Visit 2 (randomisation)

- Uncontrolled or untreated severe hypertension defined as systolic blood pressure above
or equal to 180 mmHg and/or diastolic blood pressure above or equal to 100 mmHg

- Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during last 12
months) or hypoglycaemic unawareness as judged by the investigator

- Life-threatening disease (e.g. cancer)